|Mr. Murray S. Kessler||CEO, Pres & Director||2.53M||N/A||1960|
|Mr. Todd W. Kingma||Exec. VP, Gen. Counsel & Sec.||822.91k||N/A||1960|
|Mr. Jeffrey R. Needham||Exec. VP & Pres of Consumer Healthcare Americas||956.17k||N/A||1956|
|Mr. Svend Andersen||Exec. VP & Pres of Consumer Healthcare International||873.63k||N/A||1962|
|Mr. Raymond P. Silcock||CFO, Principal Accounting Officer & Exec. VP||N/A||N/A||1951|
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, minerals and dietary supplements, feminine hygiene, diabetes care, scar management, and anti-parasite categories under the Good Sense, Sergeant's, Sentry, Zephrex D, PetArmor, and ScarAway brand names. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force. It operates in Europe, Australia, Israel, Mexico, the United States, Canada, and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Perrigo Company plc’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 4; Compensation: 2.